Highlights of This Issue 3359

SPECIAL FEATURES

CCR Translations

3361 MET as a Target in Papillary Renal Cell Carcinoma
  André P. Fay, Sabina Signoretti, and Toni K. Choueiri
  See related article, p. 3411

CCR Perspectives in Drug Approval

3364 U.S. Food and Drug Administration Inspections of Clinical Investigators: Overview of Results from 1977 to 2009
  Sonia K. Morgan-Linnell, David J. Stewart, and Razelle Kurzrock

Statistics in Clinical Cancer Research

3371 Blocking and Randomization to Improve Molecular Biomarker Discovery
  Li-Xuan Qin, Qin Zhou, Faina Bogomolniy, Liliana Villafania, Narciso Olvera, Magali Cavatore, Jaya M. Satagopan, Colin B. Begg, and Douglas A. Levine

Molecular Pathways

3379 Molecular Pathways: CDK4 Inhibitors for Cancer Therapy
  Mark A. Dickson

3384 Molecular Pathways: Niches in Metastatic Dormancy
  Kenji Yumoto, Matthew R. Eber, Janice E. Berry, Russell S. Taichman, and Yusuke Shiozawa

Review

3390 Infusions of Allogeneic Natural Killer Cells as Cancer Therapy
  Wing Leung

HUMAN CANCER BIOLOGY

3401 Efficient Identification of Mutated Cancer Antigens Recognized by T Cells Associated with Durable Tumor Regressions
  Yong-Chen Lu, Xin Yao, Jessica S. Crystall, Yong F. Li, Mona El-Gamil, Colin Gross, Lindy Davis, Mark E. Dudley, James C. Yang, Yardena Samuels, Steven A. Rosenberg, and Paul F. Robbins

3411 MET Is a Potential Target across All Papillary Renal Cell Carcinomas: Result from a Large Molecular Study of pRCC with CGH Array and Matching Gene Expression Array
  Laurence Albiges, Justine Guegan, Audrey Le Formal, Virginie Verkarre, Nathalie Rioux-Leclercq, Mathilde Sibony, Jean-Christophe Bernhard, Philippe Camparo, Zahra Merabet, Vincent Molinie, Yves Allory, Cedric Orear, Sophie Coudé, Sophie Gad, Jean-Jacques Patard, and Bernard Escudier
  See related article, p. 3361

3422 Prevailing Role of Contact Guidance in Intrastromal T-cell Trapping in Human Pancreatic Cancer
  Natalie Hartmann, Nathalia A. Giese, Thomas Giese, Isabel Poschke, Rienk Offringa, Jens Werner, and Eduard Ryschich

3434 Overexpression of Sirt7 Exhibits Oncogenic Property and Serves as a Prognostic Factor in Colorectal Cancer
  Hongyan Yu, Wen Ye, Jiangxue Wu, Xiangqi Meng, Ran-qi Liu, Xiaofang Ying, Yi Zhou, Hui Wang, Changchuan Pan, and Wenlin Huang

CANCER THERAPY: PRECLINICAL

3446 Effects of MAPK and PI3K Pathways on PD-L1 Expression in Melanoma
  Mohammad Atefi, Earl Avramidis, Amanda Lassen, Deborah J.L. Wong, Lidia Robert, David Foulad, Michael Cerniglia, Björn Titz, Thinle Chodon, Thomas G. Graeber, Begonya Comin-Anduix, and Antoni Ribas
### Table of Contents

<table>
<thead>
<tr>
<th>Page</th>
<th>Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>3472</td>
<td>Regorafenib Inhibits Colorectal Tumor Growth through PUMA-Mediated Apoptosis Dongshi Chen, Liang Wei, Jian Yu, and Lin Zhang</td>
</tr>
<tr>
<td>3485</td>
<td>Synergistic Anticancer Effects of Pam3CSK4 and Ara-C on B-Cell Lymphoma Cells Sae-Kyung Lee, Jyh Y. Chwee, Cheryl A.P. Ma, Nina Le Bert, Caleb W. Huang, and Stephan Gasser</td>
</tr>
<tr>
<td>3496</td>
<td>Importance of EGFR/ERCC1 Interaction Following Radiation-Induced DNA Damage Gianmaria Liccardi, John A. Hartley, and Daniel Hochhauser</td>
</tr>
<tr>
<td>3521</td>
<td>Old Drug New Use—Amoxapine and Its Metabolites as Potent Bacterial β-Glucuronidase Inhibitors for Alleviating Cancer Drug Toxicity Ren Kong, Timothy Liu, Xiaoping Zhu, Syed Ahmad, Alfred L. Williams, Alexandra T. Phan, Hong Zhao, John E. Scott, Li-An Yeh, and Stephen T.C. Wong</td>
</tr>
<tr>
<td>3531</td>
<td>In Vivo Fluorescence Lifetime Imaging for Monitoring the Efficacy of the Cancer Treatment Yasaman Ardestipour, Victor Chernomordik, Moinuddin Hassan, Rafal Zielinski, Jacek Capala, and Amir Gandjakhche</td>
</tr>
<tr>
<td>3550</td>
<td>Treatment Response Evaluation Using 18F-FDOPA PET in Patients with Recurrent Malignant Glioma on Bevacizumab Therapy Johannes Schwarzenberg, Johannes Czernin, Timothy F. Cloughesy, Benjamin M. Ellingson, Whitney B. Pope, Tristan Grogan, David Elashoff, Cheri Geist, Daniel H.S. Silverman, Michael E. Phelps, and Wei Chen</td>
</tr>
<tr>
<td>3560</td>
<td>Variability in Assessing Treatment Response: Metastatic Colorectal Cancer as a Paradigm Binsheng Zhao, Shing M. Lee, Hyun-Ju Lee, Yongliang Tan, Jing Qi, Thorsten Persigehl, David P. Mozeley, and Lawrence H. Schwartz</td>
</tr>
</tbody>
</table>

### CANCER THERAPY: CLINICAL

<table>
<thead>
<tr>
<th>Page</th>
<th>Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>3581</td>
<td>A Phase I Trial of LY2510924, a CXCR4 Peptide Antagonist, in Patients with Advanced Cancer Matthew D. Galsky, Nicholas J. Vogelzang, Paul Conkling, Eyas Raddad, John Polzer, Stephanie Roberson, John R. Stille, Mansoor Saleh, and Donald Thornton</td>
</tr>
<tr>
<td>3589</td>
<td>Identification of Campath-1 (CD52) as Novel Drug Target in Neoplastic Stem Cells in 5q-Patients with MDS and AML Katharina Blatt, Harald Herrmann, Gregor Hoermann, Michael Willmann, Sabine Cerny-Reiterer, Irina Sadovnik, Susanne Hemdlhofer, Berthold Streubel, Werner Rabitsch, Wolfgang R. Speer, Matthias Mayerhofer, Thomas Rulicke, and Peter Valenti</td>
</tr>
</tbody>
</table>
Phase II Study of Cediranib in Patients with Advanced Gastrointestinal Stromal Tumors or Soft-Tissue Sarcoma
Ian Judson, Michelle Scurr, Kate Gardner, Elizabeth Barquin, Marcelo Marotti, Barbara Collins, Helen Young, Juliane M. Jürgensmeier, and Michael Leahy

Prognostic and Therapeutic Implications of Aromatase Expression in Lung Adenocarcinomas with EGFR Mutations
Mikihiro Kohno, Tatsuro Okamoto, Kenichi Suda, Mototsugu Shimokawa, Hirokazu Kitahara, Shinichiro Shimamatsu, Hideyuki Konishi, Tsukihisa Yoshida, Mitsuhito Takenoya, Tokuiro Yano, and Yoshihiko Maehara

SNPs in PI3K-PTEN-mTOR and Brain Metastases in NSCLC—Letter
Abolfazl Avan, Mina Maftouh, Amir Avan, Carmelo Tibaldi, Paolo A. Zucali, and Elisa Giovannetti

SNPs in PI3K-PTEN-mTOR and Brain Metastases in NSCLC—Response
Qianxia Li, Huihua Xiong, and Xianglin Yuan

Loss of S6 phosphorylation as a biomarker of response to PI3K/mTOR pathway inhibition. The representative image shows immunohistochemical staining for phosphorylated S6 protein (ser235-236) in SUM190 breast cancer cell line xenografts treated with the pan-PI3K inhibitor BKM120. For details, see the article by O’Brien and colleagues on page 3507 of this issue.